{"id":259,"date":"2024-01-07T10:00:00","date_gmt":"2024-01-07T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=259"},"modified":"2025-09-08T11:08:28","modified_gmt":"2025-09-08T11:08:28","slug":"china-bd-2024-allorion-and-avenzo-enters-a-1-billion-usd-license-on-cdk2-inhibitor-avzo-021-arts-021","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/259.html","title":{"rendered":"[China BD 2024] Allorion and Avenzo enters a 1 billion USD License on CDK2 Inhibitor AVZO-021 (ARTS-021)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2024-01-04 (January\u00a0 4, 2024)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: AVZO-021 (ARTS-021)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor (Seller): Allorion Therapeutics (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): Avenzo Therapeutics (US)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: Small Molecule<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target: cyclin-dependent kinase 2 (CDK2) selective inhibitor<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication: advanced solid tumors<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: Phase I<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Avenzo will develop and commercialize AVZO-021 (formerly ARTS-021)  globally (excluding Greater China). <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Allorion will receive<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upfront payment of $40 million,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development, regulatory and commercial milestones and tiered royalties on net sales by Avenzo. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential payments for both programs may total more than $1 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/avenzotx.com\/press-releases\/avenzo-therapeutics-announces-global-license-of-avzo-021-arts-021-a-potentially-best-in-class-clinical-stage-cdk2-inhibitor-from-allorion-therapeutics\/\">Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics | Avenzo Therapeutics (avenzotx.com)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of Allorion Therapeutics, \u5b89\u9510\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-01-04 (January\u00a0 4, 2024) Asset Name: AVZO-021 (ARTS-021) Licensor (Seller): Allorion Therapeutics (China) Licensee &hellip; <a title=\"[China BD 2024] Allorion and Avenzo enters a 1 billion USD License on CDK2 Inhibitor AVZO-021 (ARTS-021)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/259.html\"><span class=\"screen-reader-text\">[China BD 2024] Allorion and Avenzo enters a 1 billion USD License on CDK2 Inhibitor AVZO-021 (ARTS-021)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-259","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=259"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/259\/revisions"}],"predecessor-version":[{"id":260,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/259\/revisions\/260"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}